Pradaxa data to be brought to health congress

Ridgefield-based Boehringer Ingelheim will present five abstracts at the European Society of Cardiology Congress, Aug. 31 to Sept. 4 in Amsterdam, providing additional data about its Pradaxa capsules.

Pradaxa is currently approved by the Federal Drug Administration to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and was the first oral anticoagulant for this malady approved by the FDA in more than 50 years.

“The broad range of data being presented at this year’s European Society of Cardiology further provides important new insights about Pradaxa,” said Dr. Sabine Luik, senior vice president for medicine and regulatory affairs and U.S. regional medical director for Boehringer Ingelheim Pharmaceuticals Inc. “Boehringer Ingelheim remains committed to advancing the body of information related to stroke and to constantly searching for new and innovative ways to improve the lives of patients with cardiovascular disorders.”

Some 800,000 patients in the U.S. have taken the medicine, filling 6 million prescriptions. Clinical trials continue for other uses.